As part of his Ph.D. in pharmacy at Université Laval, Dr. Audet-Walsh focused on the link between steroid hormones and endometrial and prostate cancers. During his work, he has demonstrated that the regulation of steroid metabolism is altered in tumor cells, notably via alterations of specific metabolic pathways. In addition, several pharmacogenomic analyses have been able to establish the link between genetic markers in steroidogenesis genes in relationship with prostate cancer progression. He then undertook a postdoctoral fellowship at McGill University, where he studied transcriptional regulation mechanisms by members of the nuclear receptor family using transcriptomic, cistromic (functional genomic) and metabolomic tools in different in vitro and in vivo models, with a particular interest in the regulation of energy metabolism. Dr. Audet-Walsh has notably demonstrated the interaction between several nuclear receptors and different cell signaling pathways in the transcriptional control of cell metabolism following various stresses. In addition, he was interested in characterizing the different waves of transcriptional regulation that involve the functional interaction between different families of transcription factors, especially in hormone-sensitive cancers.

Recently recruited at the Centre de recherche du CHU de Québec – Laval University, Dr. Audet-Walsh specializes in the study of metabolic reprogramming in hormone-sensitive cancers, by nuclear receptors. By their actions, these receptors act as master regulators of the cellular bioenergetic pathways, necessary for both the synthesis of ATP and the biosynthesis of macromolecules that are essential to cell proliferation. By using transcriptomic, cistromic and metabolomic analyzes, he wants to understand how these receptors contribute to the transcriptional regulation of different cellular metabolic pathways in physiology and disease. In addition, he also wants to understand how metabolism in turn influences hormonal signaling, since several metabolic intermediates are essential for the regulation of the epigenome. Finally, a translational research approach targeting the key elements of metabolism in pathological conditions will be used to validate its results in a context of in vitro (cells in culture) and in vivo (rodent models, human samples) models. Understanding the metabolic reprogramming associated with pathological conditions, as well as the factors that control such reprogramming, will allow the identification of new therapeutic targets in different hormone-sensitive cancers.

CHUL
2705 Boulevard Laurier
R-4714
Québec, QC
Canada G1V 4G2
34 entries « 1 of 4 »

Lacouture A, Lafront C, Peillex C, Pelletier M, Audet-Walsh É

Impacts of endocrine-disrupting chemicals on prostate function and cancer.

Journal Article

Environ Res, 204 (Pt B), 2021.

Abstract | Links:

Lacouture A, Jobin C, Weidmann C, Berthiaume L, Bastien D, Laverdière I, Pelletier M, Audet-Walsh É

A FACS-Free Purification Method to Study Estrogen Signaling, Organoid Formation, and Metabolic Reprogramming in Mammary Epithelial Cells.

Journal Article

Front Endocrinol (Lausanne), 12 , 2021.

Abstract | Links:

Poluri RT, Paquette V, Allain EP, Lafront C, Joly-Beauparlant C, Weidmann C, Droit A, Guillemette C, Pelletier M, Audet-Walsh E

KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism.

Journal Article

Endocr Relat Cancer, 28 (4), 2021.

Abstract | Links:

Lafront C, Germain L, Weidmann C, Audet-Walsh E

A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation.

Journal Article

Sci Rep, 10 (1), 2020.

Abstract | Links:

Vernier M, McGuirk S, Dufour CR, Wan L, Audet-Walsh E, St-Pierre J, Giguere V

Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4.

Journal Article

Oncogene, 39 (41), 2020.

Abstract | Links:

Vernier M, Dufour CR, McGuirk S, Scholtes C, Li X, Bourmeau G, Kuasne H, Park M, St-Pierre J, Audet-Walsh E, Giguere V

Estrogen-related receptors are targetable ROS sensors.

Journal Article

Genes Dev, 34 (7-8), 2020.

Abstract | Links:

Germain L, Lafront C, Beaudette J, Karthik Poluri RT, Weidmann C, Audet-Walsh E

Alternative splicing regulation by the androgen receptor in prostate cancer cells.

Journal Article

J Steroid Biochem Mol Biol, 202 , 2020.

Abstract | Links:

Audet-Walsh E, Lin SX, Wang XQ

Using Omics to better understand steroid biosynthesis, metabolism, and functions.

Journal Article

J Steroid Biochem Mol Biol, 202 , 2020.

| Links:

Levesque E, Labriet A, Hovington H, Allain EP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Audet-Walsh E, Simonyan D, Fradet Y, Lacombe L, Guillemette C

Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.

Journal Article

Br J Cancer, 122 (7), 2020.

Abstract | Links:

Poluri RTK, Beauparlant CJ, Droit A, Audet-Walsh E

RNA sequencing data of human prostate cancer cells treated with androgens.

Journal Article

Data Brief, 25 , 2019.

Abstract | Links:

34 entries « 1 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Bourse de soutien aux nouveaux détenteurs de Chaire de recherche du Canada, from 2020-07-01 to 2022-06-30
  • Canada Research Chair in Targeting metabolic vulnerabilities for the treatment of hormone-sensitive cancers, from 2020-07-01 to 2025-06-30
  • Étude de criblage sur la reprogrammation du métabolisme, du micro-environnement tumoral et des cellules souches cancéreuses dans le médulloblastome, from 2021-05-01 to 2022-04-30
  • Functional interaction between the androgen and the estrogen signalling pathways in prostate cancer, from 2018-10-01 to 2023-03-31
  • Génomique fonctionnelle des récepteurs aux hormones stéroïdiennes dans le contrôle du métabolisme énergétique des cellules de cancer de la prostate, from 2019-07-01 to 2023-06-30
  • Inhibition of the AMPK metabolic program for the treatment of prostate cancer, from 2019-08-01 to 2022-07-31
  • Regulation of Cellular Energy Metabolism in Mammary Epithelial Cells, from 2019-04-01 to 2024-03-31
  • Targeting metabolic vulnerabilities for the treatment of prostate cancer, from 2019-07-01 to 2021-12-31

Recently finished projects

  • Deciphering the role of KLF5 and NFYA in prostate cancer, from 2018-09-01 to 2021-03-31
  • Génomique fonctionnelle des récepteurs aux hormones stéroïdiennes dans le contrôle du métabolisme énergétique des cellules de cancer de la prostate, from 2019-07-01 to 2020-06-30
  • Regulation of Cellular Energy Metabolism in Mammary Epithelial Cells, from 2019-04-01 to 2020-03-31
  • Targeting the estrogen signaling pathway to treat prostate cancer, from 2018-12-01 to 2019-11-30
Data provided by the Université Laval research projects registery